EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience

A Martínez-Doménech, V Zaragoza-Ninet, A Esteve-Martínez, A García-Rabasco, J L Sánchez-Carazo, A Pérez-Ferriols

Actas Dermo-Sifiliográficas · 2024

DOI: 10.1016/j.ad.2023.10.006 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Actas Dermo-Sifiliográficas, 2024. Verfasst von A Martínez-Doménech und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dupilumab is a new targeted therapy for severe atopic dermatitis (AD) with limited real-world evidence. OBJECTIVE: Explore our experience with dupilumab for AD in clinical practice at a tertiary care center. MATERIAL AND METHOD: Unicentric observational retrospective study including adult and pediatric patients with severe AD receiving dupilumab between December 2017 and December 2021. The Eczema Area and Severity Index (EASI) score, Pruritus Numerical Rating Scale (P-NRS) and Sleep disturbance Numerical Rating Scale (S-NRS) were recovered to assess severity and response. RESULTS: Fifty-nine patients received dupilumab: 52, 48, 26 and 13 patients reached 6, 12, 24 and 36 months of treatment, respectively. The EASI-75 response rates were 94.2%, 95.8%, 92.3% and 100% at months 6, 12, 24 and 36. The EASI-90 response rates were 63.5%, 72.9%, 84.6% and 92.3% at months 6, 12, 24 and 36. The EASI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAdultChildHumansAntibodies, Monoclonal, HumanizedDouble-Blind MethodPruritusRetrospective StudiesSeverity of Illness IndexTreatment Outcome

Stichwörter der Autor:innen

Atopic dermatitisClinical practiceDermatitis atópicaDermatologic therapyDupilumabEccemaEczemaPráctica clínicaTratamiento dermatológico

Substanzen

Antibodies, Monoclonal, Humanizeddupilumab

Autor:innen und Institutionen

  • Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain.
  • Department of Dermatology, Hospital General Universitario de Valencia, Valencia, Spain. Electronic address: viozaragozaninet@gmail.com.

Zitieren

APA

Martínez-Doménech, A., Zaragoza-Ninet, V., Esteve-Martínez, A., García-Rabasco, A., Sánchez-Carazo, J. L., & Pérez-Ferriols, A. (2024). Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2023.10.006

Vancouver

Martínez-Doménech A, Zaragoza-Ninet V, Esteve-Martínez A, García-Rabasco A, Sánchez-Carazo JL, Pérez-Ferriols A. Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience. Actas Dermo-Sifiliográficas. 2024. doi:10.1016/j.ad.2023.10.006

BibTeX
@article{MartnezDomnech2024,
  author = {Martínez-Doménech, A and Zaragoza-Ninet, V and Esteve-Martínez, A and García-Rabasco, A and Sánchez-Carazo, J L and Pérez-Ferriols, A},
  title = {Efficacy and Safety of Dupilumab for the Treatment of Severe Atopic Dermatitis in Clinical Practice: A Single Center Experience},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2024},
  doi = {10.1016/j.ad.2023.10.006}
}
Kostenlos starten →